Literature DB >> 17223998

Characterization of the IGF system in 15 patients with Alström syndrome.

Pietro Maffei1, Mara Boschetti, Jan D Marshall, Richard B Paisey, Sebastian Beck, Eugenia Resmini, Gayle B Collin, Jürgen K Naggert, Gabriella Milan, Roberto Vettor, Francesco Minuto, Nicola Sicolo, Antonella Barreca.   

Abstract

BACKGROUND: Alström syndrome (ALMS) is a rare recessively inherited progressive disease (OMIM 203800). Among its diverse spectrum of clinical features are phenotypes associated with deficiencies of the GH/IGF-I axis, including short stature, obesity, insulin resistance, hypertriglyceridaemia and heart failure. PATIENTS AND MEASUREMENTS: To characterize the IGF system in ALMS, we evaluated a subset of 15 young adults with ALMS for hepatic, renal and thyroid function. Glycaemic and hormone measurements such as insulin, GH, FSH, LH, testosterone and 17-beta-oestradiol were clinically assessed. In addition, we measured IGF-I, IGF-II, IGF binding-protein-3 (IGFBP-3) and acid labile subunit (ALS - the subunits that constitute the main somatomedin complex in the circulation), and IGFBP-1 and IGFBP-2 (known to influence the bioavailability of the IGFs).
RESULTS: A significantly lower height was observed in ALMS patients compared to age-matched controls. ALMS patients were clinically obese (by weight and body mass index (BMI) standards) and leptin levels correlated with BMI. Renal and hepatic dysfunction was implicated in some patients by increased values of blood urea nitrogen (BUN) and creatinine, and transaminases, respectively. One-third of the patients presented with fasting hyperglycaemia and 80% were hyperinsulinaemic. TSH was slightly increased in 20% of patients. Baseline FSH and LH in females were within the normal range, while half of the males had abnormally low testosterone values. Male patients with hypogonadism showed significantly lower testosterone, oestrogen and ALS levels. Baseline GH values were not found to be increased. ALS and IGFBP-1 were significantly reduced and IGFBP-2 was markedly increased in ALMS patients compared to age-matched controls. The IGFs and IGFBPs were not significantly different between males and females affected with ALMS. No significant association was observed between IGFs or IGFBPs levels and weight, height, BMI, glycaemia, hyperinsulinaemia and testosterone levels. However, we found a significant association of gamma-glutamyltransferase (GGT) with IGFBP-2. IGF-I levels were significantly associated with LH in female patients.
CONCLUSIONS: In summary, the reduction of ALS and the increase of IGFBP-2 points to a growth hormone deficiency (GHD) condition in ALMS. However, further tests, including GH dynamics, are needed to determine whether, or to what degree disturbances in the GH/IGF axis contribute to the relatively short stature.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17223998     DOI: 10.1111/j.1365-2265.2007.02721.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

1.  Alström Syndrome: Mutation Spectrum of ALMS1.

Authors:  Jan D Marshall; Jean Muller; Gayle B Collin; Gabriella Milan; Stephen F Kingsmore; Darrell Dinwiddie; Emily G Farrow; Neil A Miller; Francesca Favaretto; Pietro Maffei; Hélène Dollfus; Roberto Vettor; Jürgen K Naggert
Journal:  Hum Mutat       Date:  2015-05-18       Impact factor: 4.878

Review 2.  Alström syndrome: insights into the pathogenesis of metabolic disorders.

Authors:  Dorothée Girard; Nikolai Petrovsky
Journal:  Nat Rev Endocrinol       Date:  2010-12-07       Impact factor: 43.330

3.  Alström syndrome: cardiac magnetic resonance findings.

Authors:  Francesco Corbetti; Renato Razzolini; Vera Bettini; Jan D Marshall; Jürgen Naggert; Francesco Tona; Gabriella Milan; Pietro Maffei
Journal:  Int J Cardiol       Date:  2012-04-10       Impact factor: 4.164

4.  Alström syndrome is associated with short stature and reduced GH reserve.

Authors:  S Romano; P Maffei; V Bettini; G Milan; F Favaretto; M Gardiman; J D Marshall; N A Greggio; G B Pozzan; G B Collin; J K Naggert; R Bronson; R Vettor
Journal:  Clin Endocrinol (Oxf)       Date:  2013-03-26       Impact factor: 3.478

5.  Pituitary morphovolumetric changes in Alström syndrome.

Authors:  Valentina Citton; Pietro Maffei; Jan D Marshall; Alessandro Baglione; Gayle B Collin; Gabriella Milan; Roberto Vettor; Jürgen K Naggert; Renzo Manara
Journal:  J Neuroradiol       Date:  2015-12-17       Impact factor: 3.447

6.  Alström syndrome: genetics and clinical overview.

Authors:  Jan D Marshall; Pietro Maffei; Gayle B Collin; Jürgen K Naggert
Journal:  Curr Genomics       Date:  2011-05       Impact factor: 2.236

Review 7.  Endocrine manifestations related to inherited metabolic diseases in adults.

Authors:  Marie-Christine Vantyghem; Dries Dobbelaere; Karine Mention; Jean-Louis Wemeau; Jean-Marie Saudubray; Claire Douillard
Journal:  Orphanet J Rare Dis       Date:  2012-01-28       Impact factor: 4.123

8.  Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series.

Authors:  Cristina Maria Mihai; Doina Catrinoiu; Marius Toringhibel; Ramona Mihaela Stoicescu; Negreanu-Pirjol Ticuta; Hancu Anca
Journal:  Cases J       Date:  2009-01-07

Review 9.  Alstrom syndrome (OMIM 203800): a case report and literature review.

Authors:  Tisha Joy; Henian Cao; Graeme Black; Rayaz Malik; Valentine Charlton-Menys; Robert A Hegele; Paul N Durrington
Journal:  Orphanet J Rare Dis       Date:  2007-12-21       Impact factor: 4.123

10.  Protection from clinical peripheral sensory neuropathy in Alström syndrome in contrast to early-onset type 2 diabetes.

Authors:  Richard B Paisey; Rosamund M Paisey; Mary P Thomson; Lynne Bower; Pietro Maffei; Julian P H Shield; Sue Barnett; Jan D Marshall
Journal:  Diabetes Care       Date:  2008-12-17       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.